Telix Pharmaceuticals(TLPPF)
$9.72+0.57 (+6.23%)
TLPPF
Telix Pharmaceuticals stock forecast
$9.72
At close:+0.57 (+6.23%)
Telix Pharmaceuticals (TLPPF) Stock Forecast & Price Target
205 Followers
TLPPF Analyst Ratings
Strong Buy
10Buy0Hold0Sell
Based on 10 analysts giving stock ratings to Telix Pharmaceuticals in the past 3 months
TLPPF Stock 12 Month Forecast
Average Price Target
$17.17▲(76.60% Upside)Based on 10 Wall Street analysts offering 12 month price targets for Telix Pharmaceuticals in the last 3 months. The average price target is $17.17 with a high forecast of $21.69 and a low forecast of $12.95. The average price target represents a 76.60% change from the last price of $9.72.
Past 12 Months12 Month ForecastJan2026Oct2026
High$21.69
Average$17.17
Low$12.95
Highest Price TargetHighest$21.69Average Price Target$17.17Lowest Price TargetLowest$12.95
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Shane Storey | Canaccord Genuity | $21.69 | buy | 123.16%Upside | Reiterated | 11/08/26 | ||
| Steven Wheen | Jarden | $14.46 | buy | 48.77%Upside | Reiterated | 11/05/26 | ||
| David Low | UBS | $17.90 | buy | 84.19%Upside | Reiterated | 11/04/26 | ||
| Laura Sutcliffe | Citi | $21.35 | buy | 119.62%Upside | Reiterated | 11/04/26 | ||
 Unknown AnalystNot Ranked | Ord Minnett | $15.15→$12.95 | buy | 33.19%Upside | Reiterated | 10/27/26 | ||
| Craig Wong-Pan | RBC Capital | $14.46 | buy | 48.77%Upside | Reiterated | 10/21/26 | ||
| David Stanton | Jefferies | $22.04→$21.69 | buy | 123.16%Upside | Reiterated | 10/21/26 | ||
| John Hester | Bell Potter | $13.08 | buy | 34.60%Upside | Reiterated | 09/21/26 | ||
| David Bailey | Morgan Stanley | $16.46 | buy | 69.32%Upside | Reiterated | 09/15/26 | ||
| Chris Cooper | J.P. Morgan | $17.61 | buy | 81.22%Upside | Reiterated | 09/14/26 | ||
| Tara Bancroft | TD Cowen | $13.77 | buy | 41.69%Upside | Reiterated | 02/19/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Shane StoreyCanaccord Genuity | BuyReiterated$21.69 | 11/08/26 | 123.16%Upside | ||
| Steven WheenJarden | BuyReiterated$14.46 | 11/05/26 | 48.77%Upside | ||
| David LowUBS | BuyReiterated$17.90 | 11/04/26 | 84.19%Upside | ||
| Laura SutcliffeCiti | BuyReiterated$21.35 | 11/04/26 | 119.62%Upside | ||
| Unknown AnalystOrd MinnettNot Ranked | BuyReiterated$15.15→$12.95 | 10/27/26 | 33.19%Upside | ||
| Craig Wong-PanRBC Capital | BuyReiterated$14.46 | 10/21/26 | 48.77%Upside | ||
| David StantonJefferies | BuyReiterated$22.04→$21.69 | 10/21/26 | 123.16%Upside | ||
| John HesterBell Potter | BuyReiterated$13.08 | 09/21/26 | 34.60%Upside | ||
| David BaileyMorgan Stanley | BuyReiterated$16.46 | 09/15/26 | 69.32%Upside | ||
| Chris CooperJ.P. Morgan | BuyReiterated$17.61 | 09/14/26 | 81.22%Upside | ||
| Tara BancroftTD Cowen | BuyReiterated$13.77 | 02/19/26 | 41.69%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Telix Pharmaceuticals
3 Months
Success Rate14/22 ratings generated profit
64%
Average Return
+19.26%
Copying David Stanton's trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +19.26% per trade.
1 Year
Success Rate21/30 ratings generated profit
70%
Average Return
+39.50%
Copying Steven Wheen's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +39.50% per trade.
2 Years
Success Rate17/30 ratings generated profit
57%
Average Return
+73.67%
Copying Steven Wheen's trades and holding each position for 2 Years would result in 56.67% of your transactions generating a profit, with an average return of +73.67% per trade.
TLPPF Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 14 | 15 | 22 | 19 | 19 |
| Buy | 4 | 5 | 16 | 17 | 14 |
| Hold | 2 | 3 | 4 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 20 | 23 | 42 | 38 | 34 |
In the current month, TLPPF has received 33 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. TLPPF average Analyst price target in the past 3 months is 17.17.
TLPPF Financial Forecast
High$0.06
Consensus$0.06
Low$0.06
TLPPF Earnings Forecast
Next quarter’s earnings estimate for TLPPF is $0.06 with a range of $0.06 to $0.06. The previous quarter’s EPS was $0.17. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$251M
Consensus$249M
Low$248M
TLPPF Sales Forecast
Next quarter’s sales forecast for TLPPF is $249.49M with a range of $247.99M to $251.00M. The previous quarter’s sales results were $479.74M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
TLPPF Stock Forecast FAQ
What is TLPPF’s average 12-month price target, according to analysts?
Based on analyst ratings, Telix Pharmaceuticals’s 12-month average price target is $17.17.
What is TLPPF’s upside potential, based on the analysts’ average price target?
Telix Pharmaceuticals has 76.60% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is TLPPF a Buy, Sell or Hold?
Telix Pharmaceuticals has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
What is Telix Pharmaceuticals’s price target?
The average price target for Telix Pharmaceuticals is $17.17. This is based on 10 12-month price targets, issued in the past 3 months. The highest analyst price target is $21.69, the lowest forecast is $12.95. The average price target represents a 76.60% increase from the current price of $9.72.
What do analysts say about Telix Pharmaceuticals?
Telix Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Street analysts.
How can I buy shares of TLPPF?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
